SPRAVATO® is a prescription nasal spray used along with an oral antidepressant to treat adults with treatment-resistant depression (TRD).
SPRAVATO® works by restoring the balance of certain chemicals in the brain, including glutamate, which is thought to play a role in depression.
Yes, SPRAVATO® is a controlled substance because it contains the active ingredient esketamine, which has a potential for abuse and dependence.
SPRAVATO® is administered as a nasal spray in a healthcare provider’s office or clinic, under the supervision of a healthcare professional.
SPRAVATO® is usually administered twice a week for the first month and then once a week or every other week, depending on the patient’s response and the healthcare provider’s recommendation.
The most common side effects of SPRAVATO® include dissociation (feeling disconnected from reality), dizziness, nausea, sedation, spinning sensation, and feeling drunk. These side effects usually occur within 2 hours of administration and typically resolve within 1-2 hours.
Coverage for SPRAVATO® may vary depending on the patient’s insurance plan. It is recommended to check with the insurance provider or the healthcare provider’s office for more information on coverage and potential out-of-pocket costs.

SPRAVATO® is administered as a nasal spray. Your healthcare provider will instruct you on how to use it.

The dosing of SPRAVATO® varies depending on your specific condition and individual needs. Your healthcare provider will determine the appropriate dosing schedule for you.

Like all medications, SPRAVATO® can cause side effects. Some common side effects include dissociation (feeling detached from reality), dizziness, nausea, sedation, vertigo, decreased feeling or sensitivity, anxiety, lethargy, increased blood pressure, vomiting, feeling drunk, and feeling abnormal.
SPRAVATO® has the potential for abuse and dependence, similar to other drugs that affect the central nervous system. It is important to follow your healthcare provider’s instructions for use and not to exceed the prescribed dose.
It is not recommended to use SPRAVATO® during pregnancy or while breastfeeding. You should discuss any potential risks and benefits with your healthcare provider.
SPRAVATO® can cause drowsiness, dizziness, and dissociation. You should not drive or operate machinery until you know how SPRAVATO® affects you.
SPRAVATO® should be stored in a refrigerator between 2°C to 8°C (36°F to 46°F). It can be stored at room temperature for up to 1 month, but should be discarded if not used after that time.

Contact Us

Primary Treatment Option?*
Preferred Location*